10-K: BioCorRx Reduces Net Loss, Boosts Revenue with Lucemyra Acquisition

BioCorRx Inc. reported a reduced net loss and a significant revenue increase in 2025, driven by a new acquisition and substantial grant funding, despite ongoing going concern doubts and internal control weaknesses.

Summary

• Net loss attributable to BioCorRx Inc. decreased to $3,440,146 in 2025 from $5,106,124 in 2024.
• Total net revenues surged to $797,244 in 2025, a 10,301.1% increase from $7,665 in 2024, primarily due to the acquisition of Lucemyra assets.
• Grant income significantly increased to $2,435,848 in 2025 from $1,473,276 in 2024, supporting BICX104 research for methamphetamine use disorder (MUD).
• The company acquired assets and assumed liabilities related to Lucemyra, an FDA-approved prescription medication for opioid withdrawal, from USWM, LLC on March 4, 2025, for an upfront purchase price of $400,000 and a 3% royalty on net sales.
• Operating expenses increased by $498,716 to $5,628,886 in 2025, mainly due to higher consulting, research and development, and royalty expenses, partially offset by decreased stock-based compensation.
• The company continues to face substantial doubt about its ability to continue as a going concern, with a working capital deficit of $7,491,731 and an accumulated deficit of $86,649,288 as of December 31, 2025.
• Management identified material weaknesses in internal control over financial reporting due to inadequately documented policies, insufficient GAAP experience for complex transactions, and insufficient staff for optimal segregation of duties.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with a low sentiment score due to persistent going concern issues, significant operating losses, and identified material weaknesses in internal controls, which overshadow the positive revenue growth and grant funding.

Positives

• Net loss attributable to BioCorRx Inc. decreased by 32.6% to $3,440,146 in 2025 from $5,106,124 in 2024.
• Total net revenues increased by 10,301.1% to $797,244 in 2025, primarily driven by supply and distribution sales from the Lucemyra acquisition.
• Grant income from NIDA for BICX104 research increased by 65.3% to $2,435,848 in 2025, providing significant funding for R&D.
• The acquisition of Lucemyra, an FDA-approved prescription medication for opioid withdrawal, diversifies the product portfolio and introduces new revenue streams.
• BICX104, an implantable naltrexone pellet, showed promising Phase I results, achieving 84 days of therapeutic naltrexone plasma concentrations with no serious adverse events.

Negatives

• The company has incurred significant losses since inception, with a net loss of $3,440,146 in 2025 and an accumulated deficit of $86,649,288.
• Negative cash flows from operations of $2,298,291 in 2025 indicate continued reliance on financing activities.
• The independent registered public accounting firm expressed substantial doubt regarding the company's ability to continue as a going concern.
• Material weaknesses were identified in internal control over financial reporting, including inadequately documented policies, insufficient GAAP experience for complex transactions, and insufficient staff for segregation of duties.
• Operating expenses increased by $498,716 in 2025, driven by higher consulting, R&D, and royalty expenses.
• The company faces a product liability risk related to the naltrexone implant procedure, with current insurance coverage potentially inadequate for future claims.
• The commercial success of programs and products depends on market acceptance by physicians, hospitals, and third-party payors, which is not guaranteed.

Risks

• Substantial doubt exists regarding the company's ability to continue as a going concern due to significant losses and negative cash flows from operations.
• The company's ability to generate significant revenues and achieve profitability depends on successfully completing product development, obtaining market approval, and generating substantial sales.
• Failure to obtain additional financing could severely limit or cease operations, dilute existing shareholders, or require relinquishing rights to technologies or products.
• Market acceptance of the BioCorRx Recovery Program and UnCraveRx Weight Loss Management Program is not assured, potentially hindering profitability if more licensed providers do not adopt them.
• The use of programs could result in product liability or similar claims, leading to substantial costs, reputational damage, and diversion of management attention.
• Success is substantially dependent on the continued service of senior management (President Louis Lucido and CEO/CFO Lourdes Felix), with no key person life insurance.
• Officers and directors have significant control (66.50% of voting equity), limiting minority shareholders' influence.
• The unavailability, reduction, or elimination of government incentives (grants) could materially adversely affect the business.
• Non-compliance with regulations of various local and federal government agencies, particularly for compounding pharmacies, could materially affect the business.
• Inability to protect or enforce intellectual property rights could impair the competitive position, with costly and time-consuming protection efforts.
• The company operates in a highly competitive industry, facing entities with superior resources and competitive advantages.
• Revisions to previously issued interim financial statements, though deemed immaterial, could adversely affect investor confidence and potentially lead to regulatory inquiries or litigation.
• The share price could be volatile, and trading volume may fluctuate substantially, affecting the ability to raise further working capital.
• The common stock is quoted on the OTCID Marketplace, with limited trading liquidity, and has been subject to Penny Stock rules, making transactions cumbersome.
• Future issuance of common stock, preferred stock, options, and warrants could dilute the interests of existing stockholders.
• Substantial future sales of common stock in the public market could cause the stock price to fall.
• Risks related to Novel Coronavirus (COVID-19) or other epidemics could significantly disrupt research and development, operations, sales, and financial results.

Future Outlook

The company anticipates continued operating losses and negative cash flows from operations in the near future as it executes development plans for 2026 and other strategic initiatives. It plans to raise additional capital through equity or debt financing to fund operations and product development. The commercial success of its programs and products, including BICX104, depends on market acceptance by physicians, hospitals, and third-party payors, which will require substantial marketing efforts.

Management Comments

• Management has developed a plan to continue operations, develop its products, and acquire technologies and assets, which includes continued control of expenses and obtaining equity or debt financing.
• Management believes that its current cash on hand will not be sufficient to fund its projected operating requirements for the next twelve months since the date of the issuance of the financial statements.

Industry Context

StockSavvy.ai notes that BioCorRx operates in the growing but highly competitive addiction treatment and weight loss markets, leveraging medication-assisted treatment (MAT) and clinical-stage drug development. The acquisition of Lucemyra, an FDA-approved opioid withdrawal medication, positions the company to capitalize on the ongoing opioid crisis, a significant public health challenge. The substantial NIDA grant for BICX104 research into methamphetamine use disorder (MUD) aligns with increasing government and public health focus on stimulant addiction, a less-addressed area compared to opioid use disorder. The company's strategy of combining pharmaceutical development with behavioral therapy programs (Beat Addiction Recovery, UnCraveRx) reflects a holistic approach gaining traction in these fields. However, the reliance on government grants and the challenges of market acceptance for new treatments are common hurdles in the biopharmaceutical sector.

Comparison to Industry Standards

• The company's clinical-stage drug development for BICX104 (naltrexone implant) for OUD and MUD places it in competition with established pharmaceutical companies developing addiction treatments, such as Alkermes (Vivitrol, an injectable naltrexone) and Indivior (Sublocade, buprenorphine extended-release injection). BICX104's Phase I results showing 84 days of therapeutic naltrexone plasma concentrations compare favorably to Vivitrol's once-a-month intramuscular injection, potentially offering improved patient compliance, a critical factor in addiction treatment adherence.
• The acquisition of Lucemyra (lofexidine hydrochloride) positions BioCorRx in the opioid withdrawal management market, competing with other symptomatic treatments and broader MAT programs. Lucemyra's FDA approval provides an immediate commercial product, a significant advantage over purely clinical-stage companies.
• The company's revenue of $797,244 and net loss of $3.44 million for 2025 are significantly smaller than those of major players in the addiction treatment space, reflecting its early-stage commercialization and heavy R&D focus. For instance, Alkermes reported net product revenues of $1.6 billion in 2023, highlighting the vast difference in scale and market penetration.
• The identified material weaknesses in internal controls are a concern, as robust internal controls are a standard expectation for publicly traded companies, especially those in the healthcare and pharmaceutical sectors where regulatory compliance is paramount. This contrasts with best practices seen in more mature, well-governed industry peers.

Management Changes

Corporate Governance

Legal Proceedings

• The company initiated litigation in 2019 against Pellecome and Dr. Orbeck, claiming misuse of confidential information for a weight loss product. The litigation was dismissed without prejudice in July 2021.
• On March 30, 2022, a judgment was entered in favor of Pellecome for $235,886 in costs and attorneys' fees, accruing 10% annual interest from October 6, 2021.
• The company filed a notice of appeal on May 27, 2022, and a motion to reverse the ruling on February 2, 2023.
• On October 4, 2023, the Court of Appeal upheld the judgment in favor of Pellecome for $222,933 in attorneys' fees.
• On January 5, 2024, an amended judgment of $332,503 was entered in favor of Pellecome for costs and attorneys' fees, plus $94,816 in accrued interest.
• On March 11, 2025, the company entered into a Settlement Agreement with Pellecome to pay $418,000 to settle the claims, with $138,000 remaining outstanding as of December 31, 2025.

Related Party Transactions

• As of December 31, 2025 and 2024, the company owed $312,249 and $302,749, respectively, in advances to Lourdes Felix (CEO, CFO, and Director), with imputed interest of $26,134 and $26,280 recognized in 2025 and 2024, respectively.
• Since September 2022 through December 2024, the company received $1,479,026 in advances from Louis C Lucido (Director and President). As of December 31, 2025 and 2024, the outstanding balance of advances from Mr. Lucido was $200,000 and $225,000, respectively, with imputed interest of $10,242 and $17,581 recognized in 2025 and 2024, respectively.
• On August 29, 2023, the company issued an unsecured promissory note for $150,000 to Louis C Lucido, which was later converted into common shares via an Exchange Agreement on April 24, 2024, along with related party advances and director fees.
• On October 14, 2024, Mr. Lucido exchanged $357,600 in related party advances and $30,000 in director fees for 1,105,218 shares of common stock.
• Since 2025, the company received an aggregate of $1,112,500 in advances from Mr. Lucido.
• On January 21, 2025, Mr. Lucido exchanged a $725,000 promissory note for 1,770,452 shares of common stock.
• On March 31, 2025, Mr. Lucido exchanged a $200,000 promissory note for 585,394 shares of common stock.
• On July 18, 2025, Mr. Lucido exchanged a $212,500 promissory note for 582,511 shares of common stock.
• As of December 31, 2025 and 2024, the company had advances from Kent Emry (Director) of $1,500.
• On September 9, 2021, the company issued an unsecured promissory note for $500,000 to Kent Emry, which was paid off on October 24, 2025, including $518,493 in interest payable.
• As of December 31, 2025 and 2024, the company's related party payable was $1,271,685 and $1,349,465, respectively, comprising compensation and interest payable to directors.
• On March 28, 2019, the company entered into a Subscription and Royalty Agreement with Louis and Carolyn Lucido CRT LLC (managed by Mr. Louis Lucido) for $3,000,000 in common stock and royalty payments on weight loss treatments.
• On April 1, 2019, the company entered into a Subscription and Royalty Agreement with the J and R Galligan Revocable Trust (managed by Mr. Joseph Galligan) for common stock and royalty payments on weight loss treatments.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from ongoing equity financings and debt conversions. The 'going concern' opinion and material weaknesses in internal controls pose substantial investment risk. The stock's penny stock status and volatility further impact liquidity and value.
• **Employees**: The company's ability to retain qualified personnel is crucial for product development and sales, but insufficient financial resources could limit this. Management changes, such as the appointment of Kate DeVarney, could bring new expertise.
• **Customers/Patients**: The acquisition of Lucemyra provides an FDA-approved product for opioid withdrawal, potentially benefiting patients. The continued development of BICX104 for OUD and MUD aims to improve treatment options and compliance. However, delayed market acceptance of programs could limit patient access.
• **Suppliers/Creditors**: The company's working capital deficit and reliance on financing pose risks to timely payments. Frequent debt amendments and conversions indicate ongoing financial strain, which could affect relationships with creditors.
• **Regulatory Authorities**: The identified material weaknesses in internal controls and the need for FDA approval for BICX104 highlight the company's ongoing engagement with regulatory bodies. Compliance with healthcare legislation (PPACA, HIPAA) is critical to avoid penalties.

Next Steps

• Continue to incur operating losses and negative cash flows as development plans for 2026 are executed.
• Seek additional equity or debt financing to fund operations and product development.
• Further improve internal control over financial reporting by enhancing access to accounting literature, identifying third-party professionals for complex accounting, and implementing additional layers of reviews in the financial close process.
• Retain additional accounting staff and support to enhance controls and procedures.
• Continue ongoing research of BICX104 for methamphetamine use disorder (MUD) with NIDA grant funding.
• Continue commercialization efforts for Lucemyra products and distribution arrangements.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by a 'substantial doubt' going concern opinion from its auditors, a significant working capital deficit of over $7 million, and persistent negative cash flows from operations. While revenue increased due to an acquisition and grant income is notable, these positives are dwarfed by the fundamental liquidity and profitability challenges. The identified material weaknesses in internal controls further undermine confidence in financial reporting. Extensive related-party transactions and continuous dilution through equity issuances to fund operations are red flags. The stock's penny stock status and high volatility add to the speculative nature. A seasoned investor would view these factors as indicative of a high-risk investment with a strong likelihood of further capital erosion.

Keywords

BioCorRx, BICX, SEC Filing, 10-K, Addiction Treatment, Opioid Use Disorder, Alcoholism Treatment, Naltrexone Implant, BICX104, Methamphetamine Use Disorder, MUD, OUD, FDA Approval, Clinical Stage Drug Development, Pharmaceuticals, Lucemyra, Opioid Withdrawal, Weight Loss Program, UnCraveRx, Beat Addiction Recovery, Grant Income, NIDA Grant, Financial Performance, Net Loss, Revenue Growth, Going Concern, Internal Controls, Capital Raise, Stock Dilution, Related Party Transactions, Corporate Governance, OTC Markets